TRC Plus for Hemophilia

Happy son rides on dad's shoulders outside in green field

Make hemophilia more predictable and affordable

Hemophilia is a genetic, incurable bleeding disorder affecting 30,000 males in the United States1. The care journey for and costs associated with hemophilia are often unpredictable, complex, and expensive for plans and patients. Individualized treatment plans can include clotting factor injections, monoclonal antibodies, or even gene therapies.

1. Institute for Clinical and Economic Review, Sept. 2022

100%

in-market factor therapy and gene therapy access through Accredo, ensuring continuity of patient care²

2. Accredo BoB blended factor discount averages for 2022, based on 500k life client and payers who were not previously enrolled in exclusive Accredo arrangements. While these factor figures are average, actual patient spend can vary widely.

$1.8M

aggregate savings driven through proprietary hemophilia-specific TRC waste management protocols³

3. Journal of Managed Care & Specialty Pharmacy: Vol 29, No 1, Jan, 2023. “Optimizing maintenance dosing of emicizumab-kxwh as prophylaxis in hemophilia A: Dosing to product labeling while minimizing drug waste”. www.jmcp.org/doi/full/10.18553/jmcp.2023.29.1.47

A self-service dashboard

to review therapy utilizations and gene therapy forecasting that projects potential impact to plan.

Therapy discounts across all hemophilia treatment options

including gene therapies at cost, and an average annual savings of $200K on non-gene therapies.⁴

4. Journal of Managed Care & Specialty Pharmacy: Vol 29, No 1, Jan, 2023. “Optimizing maintenance dosing of emicizumab-kxwh as prophylaxis in hemophilia A: Dosing to product labeling while minimizing drug waste”. www.jmcp.org/doi/full/10.18553/jmcp.2023.29.1.47

A comprehensive care model

with dedicated TRC specialists, in-home and virtual care options, and multi-level waste reduction through our Blood Disorder TRC.